Therapeutics

Alpha-1 antitrypsin augmentation therapy

Michael A Campos, Jorge Lascano

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Subjects with alpha-1 antitrypsin deficiency who develop pulmonary disease are managed following general treatment guidelines, including disease management interventions. In addition, administration of intravenous infusions of alpha-1 proteinase inhibitor (augmentation therapy) at regular schedules is a specific therapy for individuals with AATD with pulmonary involvement. This chapter summarizes the manufacturing differences of commercially available formulations and the available evidence of the effects of augmentation therapy. Biologically, there is clear evidence of in vivo local antiprotease effects in the lung and systemic immunomodulatory effects. Clinically, there is cumulative evidence of slowing lung function decline and emphysema progression. The optimal dose of augmentation therapy is being revised as well as more individualized assessment of who needs this therapy.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages249-262
Number of pages14
Volume1639
DOIs
StatePublished - 2017

Publication series

NameMethods in Molecular Biology
Volume1639
ISSN (Print)1064-3745

Fingerprint

alpha 1-Antitrypsin
Lung
Therapeutics
alpha 1-Antitrypsin Deficiency
Needs Assessment
Emphysema
Disease Management
Protease Inhibitors
Intravenous Infusions
Lung Diseases
Appointments and Schedules
Guidelines

Keywords

  • Alpha-1 antitrypsin deficiency
  • Alpha-1 proteinase inhibitor
  • Augmentation therapy
  • Clinical trials
  • COPD
  • Emphysema

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Campos, M. A., & Lascano, J. (2017). Therapeutics: Alpha-1 antitrypsin augmentation therapy. In Methods in Molecular Biology (Vol. 1639, pp. 249-262). (Methods in Molecular Biology; Vol. 1639). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-7163-3_25

Therapeutics : Alpha-1 antitrypsin augmentation therapy. / Campos, Michael A; Lascano, Jorge.

Methods in Molecular Biology. Vol. 1639 Humana Press Inc., 2017. p. 249-262 (Methods in Molecular Biology; Vol. 1639).

Research output: Chapter in Book/Report/Conference proceedingChapter

Campos, MA & Lascano, J 2017, Therapeutics: Alpha-1 antitrypsin augmentation therapy. in Methods in Molecular Biology. vol. 1639, Methods in Molecular Biology, vol. 1639, Humana Press Inc., pp. 249-262. https://doi.org/10.1007/978-1-4939-7163-3_25
Campos MA, Lascano J. Therapeutics: Alpha-1 antitrypsin augmentation therapy. In Methods in Molecular Biology. Vol. 1639. Humana Press Inc. 2017. p. 249-262. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-7163-3_25
Campos, Michael A ; Lascano, Jorge. / Therapeutics : Alpha-1 antitrypsin augmentation therapy. Methods in Molecular Biology. Vol. 1639 Humana Press Inc., 2017. pp. 249-262 (Methods in Molecular Biology).
@inbook{2ee1ef201b954454a93bc825773cc8a7,
title = "Therapeutics: Alpha-1 antitrypsin augmentation therapy",
abstract = "Subjects with alpha-1 antitrypsin deficiency who develop pulmonary disease are managed following general treatment guidelines, including disease management interventions. In addition, administration of intravenous infusions of alpha-1 proteinase inhibitor (augmentation therapy) at regular schedules is a specific therapy for individuals with AATD with pulmonary involvement. This chapter summarizes the manufacturing differences of commercially available formulations and the available evidence of the effects of augmentation therapy. Biologically, there is clear evidence of in vivo local antiprotease effects in the lung and systemic immunomodulatory effects. Clinically, there is cumulative evidence of slowing lung function decline and emphysema progression. The optimal dose of augmentation therapy is being revised as well as more individualized assessment of who needs this therapy.",
keywords = "Alpha-1 antitrypsin deficiency, Alpha-1 proteinase inhibitor, Augmentation therapy, Clinical trials, COPD, Emphysema",
author = "Campos, {Michael A} and Jorge Lascano",
year = "2017",
doi = "10.1007/978-1-4939-7163-3_25",
language = "English (US)",
volume = "1639",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "249--262",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Therapeutics

T2 - Alpha-1 antitrypsin augmentation therapy

AU - Campos, Michael A

AU - Lascano, Jorge

PY - 2017

Y1 - 2017

N2 - Subjects with alpha-1 antitrypsin deficiency who develop pulmonary disease are managed following general treatment guidelines, including disease management interventions. In addition, administration of intravenous infusions of alpha-1 proteinase inhibitor (augmentation therapy) at regular schedules is a specific therapy for individuals with AATD with pulmonary involvement. This chapter summarizes the manufacturing differences of commercially available formulations and the available evidence of the effects of augmentation therapy. Biologically, there is clear evidence of in vivo local antiprotease effects in the lung and systemic immunomodulatory effects. Clinically, there is cumulative evidence of slowing lung function decline and emphysema progression. The optimal dose of augmentation therapy is being revised as well as more individualized assessment of who needs this therapy.

AB - Subjects with alpha-1 antitrypsin deficiency who develop pulmonary disease are managed following general treatment guidelines, including disease management interventions. In addition, administration of intravenous infusions of alpha-1 proteinase inhibitor (augmentation therapy) at regular schedules is a specific therapy for individuals with AATD with pulmonary involvement. This chapter summarizes the manufacturing differences of commercially available formulations and the available evidence of the effects of augmentation therapy. Biologically, there is clear evidence of in vivo local antiprotease effects in the lung and systemic immunomodulatory effects. Clinically, there is cumulative evidence of slowing lung function decline and emphysema progression. The optimal dose of augmentation therapy is being revised as well as more individualized assessment of who needs this therapy.

KW - Alpha-1 antitrypsin deficiency

KW - Alpha-1 proteinase inhibitor

KW - Augmentation therapy

KW - Clinical trials

KW - COPD

KW - Emphysema

UR - http://www.scopus.com/inward/record.url?scp=85029429850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029429850&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7163-3_25

DO - 10.1007/978-1-4939-7163-3_25

M3 - Chapter

VL - 1639

T3 - Methods in Molecular Biology

SP - 249

EP - 262

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -